The report said that Governors Christopher Waller and Michelle Bowman may oppose Fed Chair Jerome Powell’s expected decision to hold interest rates steady. If both dissent, it would mark the first ...

The Japanese yen’s USDJPY pair fell 0.4% after advancing sharply in recent sessions, with focus squarely on the BOJ’s ...

Investing.com-- Asian stock markets were mixed on Wednesday, with Australia gaining on a soft quarterly inflation print, though investors remained cautious ahead of key central bank decisions from the ...

CPI inflation rose 0.7% quarter-on-quarter in Q2, less than expectations of 0.8%, data from the Australian Bureau of ...

Investing.com-- U.S. stock futures were little changed on Tuesday evening after the S&P 500 and Nasdaq snapped their winning streak, as investors digested a deluge of corporate earnings and awaited ...

Still, strength in the dollar, ahead of Wednesday’s Fed decision, put some pressure on oil prices. Nonfarm payrolls data, a key labor market indicator, is due on Friday. Trump’s deadline for steep ...

Investing.com-- A proposal by Senator Josh Hawley to ban stock trading by lawmakers is triggering tensions within the ...

Investing.com -- Cardiff Oncology Inc (NASDAQ: CRDF) reported second-quarter earnings that missed analyst expectations, sending shares tumbling 22% as investors reacted to the wider-than-expected loss ...

The company ended the quarter with $510 million in debt and net debt of $479 million, up from $498 million and $464 million respectively at the end of the first quarter. Ryerson’s board declared a ...

The footwear manufacturer posted adjusted earnings of $0.55 per diluted share for the quarter ended June 30, 2025, more than double the analyst estimate of $0.25. Revenue climbed 7.5% YoY to $105.6 ...

BlueLinx’s performance was hampered by challenging market conditions despite volume increases in both specialty and structural products. Gross profit declined 2% YoY to $120 million, with gross margin ...

Investing.com -- Aclaris Therapeutics Inc (NASDAQ: ACRS) stock surged 20% in after-hours trading following the announcement of positive top-line results from its Phase 2a trial of ATI-2138 in patients ...